ResearcherMayo ClinicActive in the last 2 years
Naga Malleswara Rao Nakka
Matched on ORCID iD 0009-0009-8360-1007; OpenAlex author ID A5049870645. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 4
- AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.celrep.2026.117777↗
- Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. Co-author DOI 10.1021/acsabm.5c02077↗
- Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in … First author DOI 10.1053/j.gastro.2024.09.009↗
- Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.mtbio.2024.101199↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hari Krishnareddy Rachamala · 4 shared papers, 2024–2026 · strength 1.01
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Krishnendu Pal · 4 shared papers, 2024–2026 · strength 1.01
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Santanu Bhattacharya · 3 shared papers, 2024–2026 · strength 0.78
- Paper Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Ef… DOI 10.1053/j.gastro.2024.09.009↗
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Paper Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenoca… DOI 10.1016/j.mtbio.2024.101199↗
- Debabrata Mukhopadhyay · 3 shared papers, 2024–2026 · strength 0.71
- Paper Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal… DOI 10.1021/acsabm.5c02077↗
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Paper Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenoca… DOI 10.1016/j.mtbio.2024.101199↗
- Hani M. Babiker · 2 shared papers, 2024–2026 · strength 0.43
- Paper AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117777↗
- Paper Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenoca… DOI 10.1016/j.mtbio.2024.101199↗
- Debabrata Mukhopadhyay · 1 shared paper, 2025 · strength 0.30
- Tanmay Kulkarni · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.